TP53 and breast carcinoma: Moreover, in breast cancers, MAGE-A2, which is up-regulated in tamoxifen-resistant tumors, localizes to the nucleus and forms complexes with p53 and estrogen receptor alpha, resulting in repression of the p53 pathway [11].